Pedersini R, et al. - In this retrospective monocentric study, researchers examined the efficacy and safety of eribulin in heavily pretreated patients with advanced breast cancer (BC) in a real-life setting. Participants in the study were patients with HER-2-negative metastatic BC, pretreated with anthracyclines and taxanes, who were referred to the Oncology Department of Spedali Civili of Brescia from May 2012 to April 2017. In heavily pretreated BC patients, researchers confirmed the activity, efficacy, and good tolerability profile of eribulin.